Through the 90-day period concluding February 19, 2026, Aligos Therapeutics's top three insider stakeholders include Director Carole Nuechterlein (441.04K shares), Chief Executive Officer Lawrence Blatt (73.90K shares), Director James Paul Scopa (7.32K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Carole Nuechterlein | 441,038 | 27 Oct, 2023 | |
| Lawrence Blatt | Chief Executive Officer | 73,903 | 27 Oct, 2023 |
| James Paul Scopa | 7,323 | 27 Oct, 2023 | |
| Thomas Woiwode | 178 | 15 Jun, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 25 Oct, 2023 | Lawrence Blatt | Common Stock | A | 610,277 | $0.76 | 73,903 | D | A |
| 25 Oct, 2023 | James Paul Scopa | Common Stock | A | 183,083 | $0.76 | 7,323 | D | A |
| 25 Oct, 2023 | Carole Nuechterlein | Common Stock | A | 7,933,601 | $0.76 | 441,038 | I | P |
| 11 Jun, 2021 | Thomas Woiwode | - | - | 0 | I | |||
| 11 Jun, 2021 | Thomas Woiwode | Common Stock | D | 9,719 | $0.00 | 0 | I | J |
| 11 Jun, 2021 | Thomas Woiwode | Common Stock | A | 2,226 | $0.00 | 178 | D | J |
| 11 Jun, 2021 | Thomas Woiwode | Common Stock | A | 9,719 | $0.00 | 389 | I | J |
| 11 Jun, 2021 | Thomas Woiwode | - | - | 0 | I | |||
| 11 Jun, 2021 | Thomas Woiwode | - | - | 389 | I | |||
| 11 Jun, 2021 | Thomas Woiwode | Common Stock | A | 8,383 | $0.00 | 335 | I | J |
| 11 Jun, 2021 | Thomas Woiwode | - | - | 335 | I | |||
| 11 Jun, 2021 | Thomas Woiwode | Common Stock | D | 485,979 | $0.00 | 58,317 | I | J |
| 11 Jun, 2021 | Thomas Woiwode | - | - | 58,317 | I | |||
| 11 Jun, 2021 | Thomas Woiwode | Common Stock | D | 8,383 | $0.00 | 0 | I | J |
| 26 Apr, 2021 | Thomas Woiwode | Common Stock | D | 8,385 | $0.00 | 0 | I | J |
| 26 Apr, 2021 | Thomas Woiwode | Common Stock | D | 9,720 | $0.00 | 0 | I | J |
| 26 Apr, 2021 | Thomas Woiwode | Common Stock | A | 2,226 | $0.00 | 89 | D | J |
| 26 Apr, 2021 | Thomas Woiwode | Common Stock | A | 9,720 | $0.00 | 389 | I | J |
| 26 Apr, 2021 | Thomas Woiwode | - | - | 89 | D | |||
| 26 Apr, 2021 | Thomas Woiwode | Common Stock | A | 8,385 | $0.00 | 335 | I | J |